Pemvidutide's Phase 2 AUD Win Sets Up FDA Discussion, But Payer and Precedent Hurdles Remain

Altimmune's Pemvidutide Significantly Reduces Heavy Drinking in Phase 2 AUD Trial

Altimmune's investigational GLP-1/glucagon injection, pemvidutide, successfully met its primary and key secondary endpoints in the Phase 2 RECLAIM study for alcohol use disorder (AUD). The trial, involving 100 patients, demonstrated a highly statistically significant reduction in heavy drinking days for participants receiving pemvidutide compared to placebo over 24 weeks. These positive topline results, coupled with a generally favorable tolerability profile, position Altimmune to request an end-of-Phase 2 meeting with the FDA to discuss the path forward for pemvidutide in AUD, highlighting its potential differentiation in the competitive landscape.

• In the Phase 2 RECLAIM study, pemvidutide achieved its primary endpoint by significantly reducing heavy drinking days. Participants treated with pemvidutide experienced an average reduction of 4.20 heavy drinking days per week from baseline, compared to a 2.75-day reduction in the placebo group over 24 weeks. Altimmune reported this treatment effect as "highly statistically significant."
• Beyond the primary endpoint, pemvidutide also met key secondary endpoints, including a higher proportion of patients achieving zero heavy drinking days in the final weeks of the study, an increased percentage of days with alcohol abstinence, and improved serum phosphatidyl ethanol levels, a biomarker of alcohol intake. The drug also demonstrated a "generally favorable" tolerability profile throughout the trial.
• Pemvidutide is a dual agonist of the GLP-1 and glucagon receptors, a mechanism that Altimmune believes offers a unique advantage in AUD treatment. The liver-directed impact of glucagon, in particular, may provide additional benefits for AUD patients, especially given the high prevalence of liver steatosis, obesity, hypertension, and hyperlipidemia in this population, potentially differentiating it from GLP-1 alone.
• Following these positive results, Altimmune plans to request an end-of-Phase 2 meeting with the FDA to determine the regulatory pathway for pemvidutide in AUD. The company also intends to present the RECLAIM study data at an upcoming scientific congress and submit it for publication in a peer-reviewed journal, while facing competition from other companies like Eli Lilly and Baseline Therapeutics in the AUD space.

Pemvidutide's Dual Agonism: Potential Beyond Alcohol Use Disorder

In addition to its investigation for alcohol use disorder, pemvidutide is being trialled for metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD). As a dual GLP-1/glucagon receptor agonist, it is positioned to provide both hepatic and systemic benefits. The intervention model, evaluated through a meta-analysis of randomized controlled trials, compared pemvidutide against placebo in adults with MASLD or MASH. These trials included assessments at both 12- and 24-week time points to evaluate efficacy and safety.

The meta-analysis demonstrated significant improvements across multiple hepatic and metabolic parameters. At the 12-week assessment, treatment with pemvidutide led to significant reductions in liver fat content (MD -52.90, 95% CI -71.60 to -34.20), CAP score (MD -38.30, 95% CI -70.69 to -5.91), body weight (MD -3.50, 95% CI -5.00 to -2.00), and blood pressure. By 24 weeks, continued benefits were observed, including significant improvements in liver enzymes ALT (MD -18.09, 95% CI -30.12 to -6.06) and AST (MD -13.02, 95% CI -21.84 to -4.20), as well as the Enhanced Liver Fibrosis (ELF) score (MD -0.44, 95% CI -0.77 to -0.11). A significant reduction in liver fat content was also maintained at 24 weeks (MD -45.51, 95% CI -52.70 to -38.33).

Regarding safety and tolerability, pemvidutide's profile was found to be comparable to that of placebo. The one notable exception was a higher incidence of mild-to-moderate nausea observed in the treatment group, though this did not reach statistical significance (P > 0.05). The collective data suggest that pemvidutide significantly improves key disease parameters in patients with MASLD/MASH with an acceptable tolerability profile. However, the analysis concluded that larger and longer-duration trials are warranted to fully confirm the drug's antifibrotic efficacy.

Pemvidutide's AUD Success: A New Frontier for Incretin Therapies

The recent positive Phase 2 results for Altimmune's pemvidutide in alcohol use disorder (AUD) signal a potentially transformative moment for both the company and the broader landscape of incretin-based therapies. While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have firmly established their utility in managing type 2 diabetes and obesity, with growing evidence of cardiovascular and renal benefits, their application in substance use disorders like AUD represents a significant expansion of their therapeutic scope.

Pemvidutide, as a dual GLP-1/glucagon receptor agonist, belongs to a class of multifunctional incretin peptides designed to leverage multiple metabolic pathways. Its success in reducing heavy drinking days in AUD patients suggests that these multi-targeting synthetic peptides may hold promise for a wider array of associated co-morbidities beyond their traditional metabolic indications. This could provide a crucial point of differentiation in an increasingly crowded GLP-1 RA market, offering a novel treatment option for a condition with limited FDA-approved therapies.

However, the path forward is not without its considerations. While the Phase 2 data is encouraging, the long-term safety and tolerability profile of pemvidutide in chronic AUD will need to be rigorously assessed in larger, longer-duration studies. GLP-1 RAs are known for gastrointestinal side effects, and while rare, some psychiatric manifestations have been observed with the class. Furthermore, the competitive landscape is evolving, with other GLP-1 RAs also being explored for various substance use disorders. Altimmune will need to clearly demonstrate pemvidutide's sustained efficacy and differentiation to carve out its market position. The regulatory journey for a novel mechanism in AUD will also require careful navigation, potentially necessitating specific endpoints or extended follow-up data to satisfy FDA requirements. Nevertheless, these results underscore the expanding potential of incretin-based therapies and could pave the way for a new era in AUD treatment.